登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TrkC】

TrkC信息

英文名称:Neurotrophic tyrosine kinase receptor type 3
中文名称:生长因子受体NT-3
靶点别称:Trk-C,NTRK3,NT-3 growth factor receptor,TrkC tyrosine kinase,Neurotrophic Receptor Tyrosine Kinase 3,Neurotrophic Tyrosine Kinase, Receptor, Type 3,GP145-TrkC,TRKC,ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein,Tyrosine Kinase Receptor C,ETV6-NTRK3 Fusion,Gp145(TrkC),Receptor, trkC,EC 2.7.10,EC:2.7.10.1,Neurotrophic Tyrosine Kinase Receptor Type 3,EC 2.7.10.1
上市药物数量:3
临床药物数量:5
最高研发阶段:批准上市

TrkC产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CHEK-ATP189
Human
HEK293/Human TrkC Stable Cell Line
TRC-H5256
Human
Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)
ACRO质量管理体系
 
评论(0)
 

TrkC分子别名

NT-3 growth factor receptor,GP145-TrkC,Neurotrophic tyrosine kinase receptor type 3, TrkC tyrosine kinase

TrkC分子背景

TrkC tyrosine kinase is also known as Trk-C receptor, NT-3 growth factor receptor and neurotrophic tyrosine kinase receptor type 3, is a member of the NTRK family which mediates the biological activities of neurotrophins. The primary location of TrkC expression is in the nervous system and, specifically, in regions of the CNS. Low level TrkC expression has also been observed in a wide variety of tissues outside the nervous system. TrkC is part of the large family of receptor tyrosine kinases which includes TrkA and TrkB. Also, there are other neurotrophic factors structurally related to NT-3: NGF, BDNF and NT-4. While TrkB mediates the effects of BDNF, NT-4 and NT-3, TrkA is bound and thereby activated only by NGF. Further, TrkC binds and is activated only by NT-3. TrkB binds BDNF and NT-4 more strongly than it binds NT-3. TrkC binds NT-3 more strongly than TrkB does. Upon neurotrophin binding, TrkC phosphorylates itself and down stream molecules of the related pathways, and therefore mediates the NT3-stimulated neurotrophic effects. This protein thus leads to cell proliferation, differentiation and plays a role in the development of proprioceptive neurons.

TrkC上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Entrectinib 恩曲替尼 NMS-E628; RXDX-101; RG-6268 批准上市 Nerviano Medical Sciences Srl Rozlytrek, 罗圣全 Japan 非小细胞肺癌 Chugai Pharmaceutical Co Ltd 2019-06-18 乳腺癌, 甲状腺乳头状瘤, 黑色素瘤, 非小细胞肺癌, 胶质瘤, 间变大细胞淋巴瘤, 急性髓细胞样白血病, 肝功能衰退, 淋巴增生性疾病, 结直肠癌, 肉瘤, 脑癌, 卵巢癌, 胆管上皮癌, 神经内分泌瘤, 中枢神经系统肿瘤, 肿瘤, 唾腺癌, 胰腺癌, 肾细胞癌, 血液肿瘤, 头颈癌, 实体瘤 详情
Larotrectinib sulfate 拉罗替尼 LOXO-101; ARRY-470; BAY-2757556 批准上市 Array Biopharma Vitrakvi, 维泰凯 United States 实体瘤 Bayer Healthcare Pharmaceuticals Inc 2018-11-26 胶质瘤, 多发性骨髓瘤, 膀胱癌, 郎格罕细胞组织细胞增生症, 骨肉瘤, 尤因肉瘤, 神经母细胞瘤, 肉瘤, 前列腺癌, 乳腺癌, 组织细胞肉瘤, 结直肠癌, 鳞状细胞癌, 中枢神经系统肿瘤, 甲状腺瘤, 非霍奇金淋巴瘤, 淋巴瘤, 肺癌, 子宫肿瘤, 子宫内膜癌, 幼年性黄色肉芽肿, 外周原始神经外胚层肿瘤, 生殖细胞和胚胎肿瘤, 黑色素瘤, 宫颈癌, 头颈部鳞状细胞癌, 实体瘤, 室管膜瘤, 纤维肉瘤, 横纹肌肉瘤, 髓母细胞瘤, 白血病, 卵巢癌, 肝癌, 头颈癌, 横纹肌样瘤, 肝胚细胞瘤, 血液肿瘤, 肾细胞癌, 食道癌, 胃癌, 直肠癌, 肿瘤, 肾母细胞瘤, 尿路上皮癌, 胰腺癌, 卵巢上皮癌, 皮肤肿瘤, 结肠癌 详情
Repotrectinib 瑞普替尼 BMS-986472; ZL-2308; TPX-0005 批准上市 Turning Point Therapeutics Inc 奥凯乐, Augtyro United States 非小细胞肺癌 Bristol-Myers Squibb Company 2023-11-15 实体瘤, 肿瘤, 中枢神经系统肿瘤, 肝功能衰退, 淋巴瘤, 脑转移, 非小细胞肺癌 详情

TrkC临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 临床三期 Kyowa Hakko Kirin Co Ltd 白血病, 髓样白血病, 骨髓瘤, 真性红细胞增多症, 前列腺癌, 神经母细胞瘤, 前体T-淋巴母细胞性淋巴瘤白血病, 急性淋巴细胞白血病, 银屑病, 骨髓纤维化, 急性髓细胞样白血病, 原发性血小板增多症 详情
Merestinib 5OGS5K699E; LY-2801653 临床二期 礼来制药 胆管癌, 实体瘤, 皮肤黑色素瘤, 骨转移, 胰腺癌, 肿瘤, 高微卫星不稳定性癌症, 乳腺癌, 胆管上皮癌, 套细胞淋巴瘤, 结直肠癌, 急性髓细胞样白血病, 非霍奇金淋巴瘤, 胆囊癌, 转移癌, 非小细胞肺癌 详情
FCN-011 FCN-011 临床二期 重庆复创医药研究有限公司 实体瘤 详情
HG-030 HG-030 临床一期 成都先导药物开发股份有限公司 实体瘤 详情
PBI-200 PBI-200 临床一期 Pyramid Biosciences 实体瘤, 促结缔组织增生性小圆细胞肿瘤, 脑癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定